Not a good buy right now for an impatient buyer: momentum is still bearish (MACD histogram negative and worsening) and the stock is trading below the key pivot (4.022).
Tactical bounce potential exists because price is sitting just above near-term support (S1=3.653) and RSI_6 (~20.6) is oversold, but the setup is not confirmed by Intellectia signals.
Best immediate-risk entry would be after a reclaim of the 4.02 pivot (or a clear MACD/RSI turn). At the current 3.74, risk of a support break remains meaningful.
Technical Analysis
Trend/momentum: MACD histogram at -0.0627 and negatively expanding => downside momentum is strengthening, not reversing yet.
RSI: RSI_6 at ~20.6 indicates oversold conditions, which can spark short bounces, but oversold alone is not a buy trigger.
Moving averages: converging MAs suggest consolidation, but with bearish momentum tilting risk lower.
Key levels: Price 3.74 is below Pivot 4.022.
Support: S1 3.653 then S2 3.425 (a break below S1 would be technically damaging).
Resistance: R1 4.39 then R2 4.618 (needs to clear pivot first).
Pattern-based forward view (provided): 70% chance of ~+0.26% next day, ~+0.94% next week, but ~-4.07% over next month => short-term stabilization, weaker 1-month bias.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning/sentiment split: Open interest put/call is very low (0.12) showing call-heavy outstanding positioning, but today’s put/call volume is very high (4.2) suggesting near-term bearish trading/hedging today.
Volatility: 30D IV ~267.6% vs historical vol ~90.6% => options are priced for large moves; sentiment is speculative and reactive.
Volume spike: today’s option volume is ~325% of the 30D average, indicating heightened attention despite limited absolute volume (26 contracts).
Technical Summary
Sell
7
Buy
6
Positive Catalysts
can produce a quick rebound if support holds.
Neutral/Negative Catalysts
despite call-heavy open interest.
Financial Performance
Latest quarter financials not available in the provided data (financial snapshot error), so growth trends and runway can’t be validated here.
As a result, this decision leans more heavily on technicals/sentiment and the existing clinical/analyst narrative rather than confirmed recent quarterly execution.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Coverage initiation (2025-12-22) by Clear Street with a Buy rating and a $9 price target.
Wall Street pro view (pros): believes Cellectis’ early efficacy signals in hematologic cancers position it to potentially be among the first to market with an allogeneic CAR-T.
Wall Street con view (cons): with no new near-term news provided and bearish technical momentum, the timing for entry looks suboptimal even if the long-term thesis is attractive.
Influential trading check: No notable hedge fund or insider trend flagged (both neutral), and no recent Congress trading data available in the last 90 days.
Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 7 USD with a low forecast of 4 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 7 USD with a low forecast of 4 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.500
Low
4
Averages
7
High
9
Current: 3.500
Low
4
Averages
7
High
9
Clear Street
Bill Maughan
initiated
$9
AI Analysis
2025-12-22
Reason
Clear Street
Bill Maughan
Price Target
$9
AI Analysis
2025-12-22
initiated
Reason
Clear Street analyst Bill Maughan initiated coverage of Cellectis with a Buy rating and $9 price target. Cellectis has produced "strong" efficacy data from its initial program, lasme-cel in acute lymphoblastic leukemia, and "an encouraging initial efficacy signal" from eti-cel in non-hodgkin's lymphoma, which the firm believes positions Cellectis well to be among the first companies to bring an allogenic CAR-T product for the treatment of hematological cancers to market.
Wells Fargo
Nick Abbott
Equal Weight
maintain
$3 -> $4
2025-10-20
Reason
Wells Fargo
Nick Abbott
Price Target
$3 -> $4
2025-10-20
maintain
Equal Weight
Reason
Wells Fargo analyst Nick Abbott raised the firm's price target on Cellectis to $4 from $3 and keeps an Equal Weight rating on the shares. The firm says new data from DL3 of ALL study are promising, with high CR/CRi & MRD-ve rates in patients with few options. Clarity on regulatory path is also positive, Wells adds. Pivotal Phase 2 execution is now key, with first data Q4 2026 and BLA filing in the second half of 2028, along with clarity on market size/opportunity.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLLS
